支气管动脉灌注化疗栓塞术联合安罗替尼治疗晚期NSCLC的临床研究

目的探究安罗替尼(Anlotinib)联合支气管动脉灌注化疗栓塞术(bronchi artery chemo-therapy embolism,BACE)治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效、安全性。方法选取2018年6月~2019年2月治疗的59例NSCLC资料,分为观察组(安罗替尼联合BACE治疗的29例患者)和对照组(BACE治疗的30例患者),观察记录患者临床疗效。结果观察组DCR(75.9%vs46.7%,P<0.05)、PFS(4.6个月vs 3.1个月,P<0.001)显著高于对照组;常见的不良反应为高血压13.8%(4/29),手足皮肤综合征10.3%(3/29),蛋白尿10.3%(3/29),乏力6.9%(2/29)等;治疗后观察组患者KPS评分好转率更高,P<0.05。结论安罗替尼联合BACE治疗NSCLC近期临床效果有一定提高、安全性高,有益于提高患者治疗后的生活质量。

Clinical study of bronchi artery chemo-therapy embolism combined with anlotinib in the treatment of advanced NSCLC

Objective To investigate the clinical efficacy and safety of anlotinib combined with bronchi artery chemo-therapy embolism(BACE)in the treatment of advanced non-small cell lung cancer.Methods The data of 59 NSCLC patients treated from June 2018 to February 2019 were collected and divided into observation group(29 patients treated with Anlotinib combined with BACE)and control group(30 patients treated with BACE).The clinical efficacy of the patients was observed and recorded.Results DCR(75.9%VS 46.7%,P<0.05)and PFS(4.6 months vs 3.1 months,P<0.001)in the observation group were significantly higher than those in the control group.The common adverse reactions were hypertension in 13.8%(4/29),hand-foot-skin syndrome in 10.3%(3/29),proteinuria in 10.3%(3/29),fatigue in 6.9%(2/29),etc.After treatment,the improvement rate of KPS score in the observation group was higher(P<0.05).Conclusion The combination of Anlotinib and BACE in the treatment of NSCLC has certain improvement in short-term clinical effect and high safety,which is beneficial to improve the quality of life of patients after treatment.